What Phio Pharmaceuticals Corp's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 7 | 12 |
| Sells | 0 | 0 |
| Total trades | 12 | 23 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 23 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Plott Ronald Todd | Director | Sep 29 | Open-market buy · P | +5,000 | $1.04 | +$5.2K | 42,000 |
| Plott Ronald Todd | Director | Sep 28 | Grant / award · A | +17,000 | — | — | 32,000 |
| Bitterman Robert J | Chairman, Pres. & CEO | Sep 28 | Grant / award · A | +400,000 | — | — | 764,871 |
| Carson Lisa Cabott | Chief Financial Officer | Sep 28 | Grant / award · A | +108,000 | — | — | 189,112 |
| Plott Ronald Todd | Director | Sep 28 | Open-market buy · P | +5,000 | $1.03 | +$5.15K | 37,000 |
| Bradford Patricia A | Director | Sep 24 | Open-market buy · P | +6,500 | $1.01 | +$6.58K | 64,151 |
| Bitterman Robert J | Chairman, Pres. & CEO | Sep 22 | Open-market buy · P | +2,000 | $1.03 | +$2.06K | 364,871 |
| Bradford Patricia A | Director | Sep 15 | Open-market buy · P | +12,000 | $1.03 | +$12.4K | 57,651 |
| Carson Lisa Cabott | Chief Financial Officer | Sep 11 | Withheld — tax / exercise cost · F | −12,888 | $1.03 | −$13.3K | 81,112 |
| Bitterman Robert J | Chairman, Pres. & CEO | Sep 11 | Withheld — tax / exercise cost · F | −68,550 | $1.03 | −$70.6K | 362,871 |
| Plott Ronald Todd | Director | Aug 19 | Open-market buy · P | +15,000 | $1.14 | +$17.1K | 15,000 |
| Bitterman Robert J | Chairman, Pres. & CEO | Aug 18 | Open-market buy · P | +10,000 | $1.06 | +$10.6K | 431,421 |
| Bitterman Robert J | Chairman, Pres. & CEO | Jun 26 | Open-market buy · P | +10,000 | $0.99 | +$9.9K | 421,421 |
| Bitterman Robert J | Chairman, Pres. & CEO | Feb 05 | Grant / award · A | +120,000 | — | — | 411,421 |
| Freeman Jonathan E | Director | Feb 05 | Grant / award · A | +16,600 | — | — | 32,655 |
| Deming David H | Director | Feb 05 | Grant / award · A | +23,800 | — | — | 37,800 |
| Lockshin Curtis | Director | Feb 05 | Grant / award · A | +16,600 | — | — | 35,155 |
| Bradford Patricia A | Director | Feb 05 | Grant / award · A | +18,500 | — | — | 45,651 |
| Carson Lisa Cabott | Chief Financial Officer | Feb 05 | Grant / award · A | +47,000 | — | — | 94,000 |
| Bitterman Robert J | Chairman, Pres. & CEO | Dec 31 | Open-market buy · P | +5,000 | $1.03 | +$5.15K | 291,421 |
Loading...
